Ser282
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser282  -  NDR2 (human)

Site Information
NRRQLAYstVGtPDy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 460298
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 4 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 10 , 12 ) , phospho-antibody ( 4 , 11 , 12 ) , western blotting ( 4 , 12 )
Disease tissue studied:
gastric cancer ( 5 ) , gastric carcinoma ( 5 ) , lung cancer ( 1 , 2 , 3 ) , non-small cell lung cancer ( 1 , 2 , 3 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 ) , non-small cell large cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 4 ) , 293F (epithelial) ( 11 ) , Calu-3 (pulmonary) ( 1 ) , COS (fibroblast) ( 11 , 12 ) , DMS153 (pulmonary) ( 3 ) , HCC78 (pulmonary) ( 2 ) , HCC827 (pulmonary) ( 1 ) , HeLa (cervical) ( 4 , 6 , 7 , 8 , 9 , 12 ) , LO2 (hepatocyte) ( 4 ) , lung ( 1 , 2 , 3 ) , MKN-45 (gastric) ( 5 ) , NCI-H1437 (pulmonary) ( 3 ) , NCI-H1650 (pulmonary) ( 1 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H1975 (pulmonary) ( 1 ) , NCI-H2073 (pulmonary) ( 3 ) , NCI-H209 (pulmonary) ( 3 ) , NCI-H2106 (pulmonary) ( 1 ) , NCI-H2228 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 2 ) , NCI-H838 (pulmonary) ( 3 ) , SW480 (intestinal) ( 10 )

Upstream Regulation
Regulatory protein:
CCND1 (human) ( 4 ) , CDK4 (human) ( 4 ) , MOB1A (human) ( 4 ) , MST1 (human) ( 4 )
Putative in vivo kinases:
NDR2 (human) ( 11 , 12 )
Treatments:
IGF-1 ( 10 ) , okadaic_acid ( 11 , 12 )

Downstream Regulation
Effects of modification on NDR2:
enzymatic activity, induced ( 10 , 11 , 12 ) , molecular association, regulation ( 4 )
Effects of modification on biological processes:
cell growth, altered ( 10 )
Induce interaction with:
CCND1 (human) ( 4 ) , MOB1A (human) ( 4 ) , MST1 (human) ( 4 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Du Z, Tong X, Ye X (2013) Cyclin D1 promotes cell cycle progression through enhancing NDR1/2 kinase activity independent of cyclin-dependent kinase 4. J Biol Chem 288, 26678-87
23897809   Curated Info

5

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

6

Zhou J (2009) CST Curation Set: 7598; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

7

Zhou J (2009) CST Curation Set: 7597; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

8

Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

9

Zhou J (2009) CST Curation Set: 7594; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

10

Suzuki A, Ogura T, Esumi H (2006) NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling. J Biol Chem 281, 13915-21
16488889   Curated Info

11

Stegert MR, et al. (2005) Regulation of NDR protein kinase by hydrophobic motif phosphorylation mediated by the mammalian Ste20-like kinase MST3. Mol Cell Biol 25, 11019-29
16314523   Curated Info

12

Stegert MR, et al. (2004) Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein. J Biol Chem 279, 23806-12
15037617   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.